|Day Low/High||133.89 / 138.64|
|52 Wk Low/High||127.80 / 189.00|
As feds remain a drag on industry, biotech has high hopes for national reform. Here, we talk with Oludare Odumosu about what could be ahead.
Here's how'd we play the stock after looking at the charts.
Here are my investment observations for Carvana and Jazz Pharmaceuticals.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
JAZZ has been upgraded to a buy recommendation by TheStreet's Quant Ratings service.
These names are showing both technical and quantitative deterioration.
Let's review the charts and indicators of this Dublin-based biopharmaceutical.
Two reasons to buy a stock are better than one. Right?
These 'Bearish Bets' are showing both technical and quantitative deterioration.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
But we could see more volatility in the market.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.